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Abstract: 
 Regulation of cell proliferation within an organism is a necessary and complex 
process involving several proteins serving as controls at various cell cycle phases known 
as cell cycle checkpoints.  One of these checkpoints, the mitotic spindle checkpoint, 
controls the advancement from metaphase to anaphase during mitosis and monitors the 
proper attachment of the microtubules to the kinetochore.  The spindle checkpoint 
protein, BubR1 is a protein kinase that localizes to the kinetochores to monitor proper 
microtubule attachment.  BubR1 is able to inhibit the anaphase promoting complex 
(APC) and delay the onset of anaphase.  Concurrent with its role in regulating cell cycle, 
mutations in BubR1 have been observed in various human cancers.  In this work, we 
examine the effects of BubR1 deficiency at the cellular and organism level using an 
inbred mouse strain that is deficient for the BubR1 gene expression.  We showed that the 
complete loss of BubR1 resulted in an embryonic lethal phenotype and this phenotype 
could not be rescued in a p53 deficient background.  Additionally, mice heterozygous for 
BubR1 showed a decreased life expectancy and an increased incidence of tumorigenesis.  
Furthermore, our data indicates that the loss of BubR1 synergizes with p53 deficiency to 
increase the susceptibility of cancer formation in mice and alters the tumor spectrum of 
the p53 deficient mice.  Finally we show that the BubR1 deficiency increases cellular 
growth kinetics and transformation potential of MEFs derived from compound BubR1; 
p53 mutants.  This data provides insight into the importance of BubR1 in the prevention 
of tumorigensis and its role as a checkpoint protein.   
 
 
 
 
 
 
 iv
 v
Table of Contents: 
     
I.  Introduction                                                                                                                1 
 A. Cancer Overview and Statistics                                                                     1 
 B. Cancer and the Cell Cycle                                                                              2 
 C. Cell Cycle Checkpoints and Mitosis                                                              4 
D. Role of p53 as a Checkpoint Protein                                                              8 
  i. Overview                                                                                              8 
  ii. Activation of p53                                                                               10 
  iii. Physiological role of p53                                                                  11 
  iv. Regulation of p53 activity                                                                 13 
  v. Effects of p53 inactivation                                                                 15 
 F. Role of BubR1 as a Checkpoint Protein                                                        16 
  i. Overview                                                                                             16 
  ii. Functional role of BubR1                                                                   19 
  iii. BubR1 activation and the mitotic spindle checkpoint                       21 
  iv. Additional functions of BubR1                                                          22 
  v. Effects of BubR1 inactivation                                                             23 
 G. Rational for Generating BubR1/p53 Compound Mutants.                             25 
 
II. Materials and Methods                                                                                                27 
A. Generation of BubR1 Mutant Mice in a p53 Deficient Background             27 
B. DNA Extraction                                                                                             28 
C. BubR1 Genotyping                                                                                         28 
D. Generation of Mouse Embryonic Fibroblasts (MEF)                                    29 
E. Cell Proliferation Assays                                                                               30 
F. Colony Forming Unit Assay (CFU)                                                              30 
G. Cell Cycle Analysis                                                                                       31 
H. Animal Husbandry                                                                                         31 
I. Southern Blotting                                                                                           32 
 
III. Results                                                                                                                       35 
A. Characterization of the BubR1 Gene Trap Insertion Site                               35 
B. BubR1 Deficiency Effects Embryogenesis                                                     35 
C. Generation of BubR1/p53 Compound Mutants.                                              38 
D. BubR1 Deficiency Enhances Tumor Formation in p53 Mutant Mice           41 
E. Gene Dosage Effect of BubR1 During Tumorigenesis                                  48 
F. BubR1 Deficiency Enhances Cell Proliferation and Cell                               48 
     Transformation Potential 
 
IV Discussion                                                                                                                    52      
      
     References                                                                                                                    56 
 
List of Tables: 
 
Table                                                                                                                         Page  
                                                                                                                       
1.  Embryonic lethality of BubR1 nullizygotes                                                           39   
2.  p53 deficiency does not rescue the lethality of the BubR1 nullizygotes                40 
3.  p53 deficiency is unable to delay the lethal phenotype observed in BubR1          42 
     nullizygotes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi
List of Figures 
 
Figure                                                                                                                          Page 
 
   1.  The stages of mitosis               .                                                                             7 
   2.  The mitotic spindle checkpoint.                                                                             9 
   3.  The BubR1 protein.                                                                                              18 
   4.  Southern blot results indicate the p53 genotype.                                                  34 
   5.  The BubR1 gene and the location of the PCR primers.                                        36 
   6.  PCR indicates the BubR1 genotype.                                                                     37 
   7.  Survival of the wild type, heterozygous, and compound heterozygous               43 
        mutant mice. 
   8.  Survival of BubR1 mutants in the p53 nullizygous background.                         45 
   9.  Tumor spectrum of the single and compound heterozygous mice.                      46 
 10.  Tumor spectrum of the single and compound nullizygous mice.                         47 
 11.  BubR1 and p53 deficiency has a synergistic effect on cellular proliferation       49 
 12.  BubR1 and p53 deficiency has a synergistic effect on the transformation           51 
        potential of MEFs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii
Nomenclature 
 
                              cpm/ml                            counts per minute per milliliter 
                                           µl                                     microliter 
µM                                  micromolar 
mg                                   milligrams 
mM                                  millimolar 
ng                                    nanograms 
 
 
 
Abbreviations 
 
           APC/C                                          anaphase promoting complex/cyclosome 
           CDC                                             cell division cycle/control 
           CDK                                             cyclin-dependent kinase 
           CFU                                              colony forming unit 
           CIN                                              chromosomal instability 
           DMEM                                         Dulboc’s modified eagle media 
           DNA                                             deoxyribonucleic acid 
           E10.5                                            embryonic day 10.5 
           E13.5                                            embryonic day 13.5 
           FBS                                              fetal bovine serum 
           G1                                                gap phase 1 
           G2                                                gap phase 2 
           M                                                 mitosis 
           MCC                                           mitotic checkpoint complex 
           MEF                                            mouse embryonic fibroblast 
           NLS                                             nuclear localization signal 
           PBS                                             phosphate buffered saline 
           Pen/Strep                                    penicillin/ streptomycin 
           RNA                                           ribonucleic acid 
           ROS                                           reactive oxygen species 
           S                                                 synthesis 
           TBP                                            TATA binding protein 
           TAF                                            TBP associated factors 
 viii
I.  Introduction: 
Cancer Overview and Statistics: 
 Cancer is a disease of uncontrolled cell growth and division (1).  In this disease, a 
single cell, through mutation, becomes unable to monitor or control its proliferation.  This 
unchecked proliferation grants a growth advantage to the cell, and with time, allows 
further mutations to accumulate within the cells created by the original cell, called clones.  
These accumulated mutations will alter the clones in such a way that they are able to 
escape regular growth control signals and, in some instances, develop the ability to 
escape their primary site, referred to as a tumor, and spread throughout the body of the 
organism (1).  Mortality is often due to the fact that the rapidly dividing cells fail to 
differentiate and perform the function they are designed to.  Alternatively, these masses 
can grow, affecting the normal functioning of adjacent organs or they can usurp the blood 
supply to the normal tissue causing the organs near the mass to fail (2).  Mammals have 
evolved a variety of mechanisms to control/regulate cellular proliferation.  However, over 
time, these control mechanisms can become compromised due to accumulation of genetic 
changes that result in uncontrolled cell growth.   
Cancer is a disease prevalent world wide, and the loss of life and costs of 
treatment have remained consistently high over the last 50 years, even though medical 
advances have lowered the mortality and cost of many other commonly seen health 
threats.  Cancer can effect any organ or tissue type, but for the purposes of this study, we 
will examine the trends of the disease overall and the statistics of colon/rectal cancer. 
According to the American Cancer Society, in 2005, cancer was the second highest cause 
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of death with 22.8% of all deaths being attributed to cancer or its complications.  Cancer 
deaths are second only to heart disease which is the leading cause of death with 28.5% of 
all deaths.  The difference between the two, 5.7%, is relatively small especially when one 
looks at the separation between the second and third leading cause of death, 
cerebrovascular diseases, which accounts for only 6.7% of all deaths.  This information 
alone would be enough to promote a desire to understand this disease, but with the actual 
number of deaths indicated, the need becomes more pressing.  It is estimated that in the 
US alone, 295,280 men and 275,000 women died from cancer in 2005.  The leading type 
of cancer for these people is lung cancer (31%), though cancers of the colon/rectum will 
cost 10% of both men and women their lives, and are the third leading cause of deaths 
from cancer.  Also, it is estimated that 710, 040 men and 662, 870 women in the US were 
diagnosed with new cases of cancer in 2005.  Again, cancers of the colon/rectum will be 
the third most common cancer to be diagnosed.  According to these statistics, one out of 
two men and one out of three women will develop cancer over the course of their lifetime 
with one out of 17 of those, for both genders, being cancers of the colon.  Also it has been 
estimated that the cost of cancer in 2003 was $189.5 billion.  Thus, it becomes apparent 
that cancer is a disease in which discovering effective treatments to prevent or reduce 
disease occurrence is an important step in promoting people’s health (2).  
 
Cancer and the Cell Cycle: 
 Since cancer is a disease caused by uncontrolled cellular division, it is first 
necessary to examine the way in which cell division occurs under normal conditions.  
Cellular division consists of four stages.  These stages are G1 (gap phase 1), S 
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(synthesis), G2 (gap phase 2), and M (mitosis).  In G1, the cell has just finished a round 
of cellular division and requires time to grow and obtain the nutrients and build the 
proteins necessary to begin the next round of cellular division.  Once the required needs 
are met, the cell will enter S phase where the cell will replicate its DNA.  DNA synthesis 
is followed by a second gap phase where, again, the cell makes sure that it has time to 
gather the necessary machinery to allow accurate and timely division as well as to assure 
the integrity of the cell’s genetic material.  Finally, during the M-phase, the cell 
undergoes mitosis and completes cellular division.  The cell cycle is conserved in all 
dividing cells and is regulated by proteins known as cyclins and their partners, the cyclin-
dependent kinases. (CDK).  The CDKs are found constitutively in the cell during all of 
the cell cycle stages.  Cyclins on the other hand, are only expressed during the stage in 
which they associate with their CDK partners.  The cyclins then are ubiquitinated and 
destroyed by the proteosome to allow progression into the next stage of the cell cycle (1, 
3, 4).  To facilitate the ubiquitination and subsequent destruction of these products, they 
contain a conserved amino acid sequence of RxxLxxxxS.  This sequence, known as the 
destruction box sequence, is found in many cyclins as well as several other cell cycle 
proteins that are regulated in a cell cycle dependent manner, such as BubR1.  One way in 
which normal cells develop a cancerous phenotype is through the improper activation or 
production of these cyclins controlling the passage of the cell from one stage of the cell 
cycle to the next (5).  
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Cell Cycle Checkpoints and Mitosis: 
 To assure the proper progression through the cell cycle, and to prevent the 
progression to the next stage before the requirements of the previous stage are met, the 
cell cycle has safeguards known as checkpoints.  These checkpoints are found at critical 
junctions of the cell cycle and allow the cell cycle to be arrested if there is DNA damage 
or if the cell cycle progression stalls due to aberrant conditions.  Upon activation of these 
checkpoints, the cell will cease the cycle at whichever point it is in until the event that 
activated the checkpoint is corrected for, allowing the cell cycle to continue.  If the 
situation is too dire, extended activation of the checkpoint will promote apoptosis.  The 
three commonly described cell cycle checkpoints are the checkpoints found at the G1/S 
transition, which allows the cell to begin DNA replication, the G2/M transition, which 
assures that the DNA was replicated without error, and the mitotic spindle checkpoint 
which helps assure that there is accurate chromosome segregation (4, 6).  A fourth cell 
cycle check point is the intra-S checkpoint, which is activated when the replication fork 
encounters DNA damage during replication.  This checkpoint enhances genomic stability 
by slowing DNA synthesis to allow time for DNA repair. (7)   
 The G1/S checkpoint is activated by DNA damage and will stall the progression 
into S-phase by preventing the firing of the replication origins or progression of the 
replication fork until the damage is repaired.  This G1/S arrest allows for repair of the 
template DNA and prevents DNA damage from becoming a fixed mutation in the cell for 
subsequent divisions.  The major players of the G1/S checkpoint include the proteins 
ATM, ATR, p53 and p21 (8).  In this checkpoint, DNA damage is sensed by ATM 
Kinase and p53 protein levels are increased.  The p53 tumor suppressor gene protein, 
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then activates several gene products leading to delay of the cell cycle progression (9).  
Once the DNA damage is repaired, the checkpoint signal is reduced through the 
destabilization and degradation of p53, and the cell is able to continue on to and through 
S-phase.   
After DNA replication, there is a second DNA damage checkpoint to assure that 
both the template and the replicated DNA are undamaged.  This occurs after replication 
but before progression into mitosis and serves to assure that the daughter cells produced 
both have DNA that is identical to the parent cell (4).  The major components of the 
G2/M checkpoint include Chk1, Chk2, and p53 proteins.  If DNA damage is detected 
during the G2-M transition phase, ATM or ATR will activate Chk1 and Chk2.  These, in 
turn, will phosphorylate and inactivate the phosphatase Cdc25c  (10, 11).  The role of 
Cdc25C is to remove an inhibiting phosphorylation on Cdc2 (tyrosine-15).  This 
inhibition of Cdc2 stops the cell cycle from progressing into M-phase until the DNA 
damage is repaired.  The p53 protein is also activated by ATM or ATR in response to 
DNA damage and serves a role similar here as in the G1/S checkpoint by inducing the 
expression of p21 that arrests the cells at the G2/M phase.  It is only after the progression 
through these two checkpoints that the cell enters M-phase and subsequent cellular 
division (6, 12). 
 Mitosis is a multi-step process in which the parent cell must condense its DNA 
into paired chromosomes, align the chromosomes along the metaphase plate, accurately 
separate the sister chromatids, and finally reform the nuclear membrane and de-condense 
the DNA.  The first step or stage of mitosis is known as prophase, and it is here that the 
nuclear membrane breaks down and the DNA begins to condense.  At this time, the sister 
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chromatids are secured together by proteins called cohesins, serving as molecular glue so 
that they can eventually be divided equally between the two daughter cells.  There is then 
an intermediate stage known as prometaphase, where the chromosomes have condensed 
and are free in the cytoplasm and the centrioles have reached the poles and begin building 
microtubules.  These microtubules will extend out into the cytoplasm and, upon making 
contact, will bind to the kinetochore of the chromosomes.  Eventually, at metaphase, the 
microtubules will align the chromosomes up in the middle of the cell with the 
microtubules attached to either side of the kinetochores.  This places tension across each 
kinetochore, signaling bipolar attachment.  Once aligned across the metaphase plate, the 
chromosomes then go through anaphase where the sister chromatids separate and move to 
the poles.  Once congregated at the poles, the chromosomes de-condense and the nuclear 
membrane reforms around each set during telophase (figure 1).  The cellular contents 
then divide in a process known as cytokinesis and the two daughter cells are now formed 
(1, 4). 
 It is during mitosis that we find the third cell cycle checkpoint, known as the 
mitotic spindle checkpoint.  In order to assure proper separation of the sister chromatids 
to the daughter cells, the chromosomes must be aligned on the metaphase plate and each 
of the chromatids must be attached to microtubules originating from opposing spindle 
poles.  Since the microtubules employ a “search and capture” method of attachment, 
progression must be delayed until all of the chromosomes are attached and tension is 
generated across the kinetochore, signaling bipolar attachment (13, 14).  It has been 
shown that the mitotic  
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Prophase Prometaphase Metaphase 
Anaphase Telophase Cytokinesis 
 
 
Figure 1:  The stages of mitosis.  This diagram shows the stages of mitosis.  In prophase and 
prometaphase the nuclear membrane breaks down and the DNA condenses.  It is here that many 
of the mitotic spindle checkpoint proteins will bind to the kinetochores of the chromosomes.    
Once condensed, microtubules will attach to the chromosomes and line them on the metaphase 
plate (metaphase) and upon alignment the sister chromatids will be separated and pulled towards 
the poles (anaphase).  Finally the chromosomes will reach the poles and de-condense and the 
nuclear membrane regenerated and the cell will divide (telophase and cytokinesis).  (images from 
http://www.metu.edu.tr/~e118872/project/index.htm) 
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spindle checkpoint signal is activated even if only a single kinetochore remains 
unattached (15).  The major components in the mammalian mitotic spindle checkpoint 
include Mad1 and Mad2, Bub1, BubR1, and Bub3 (16).  These proteins all localize to the  
kinetochores of unattached microtubules during prometaphase and become activated 
during metaphase, where they create a complex known as the Mitotic checkpoint 
complex (MCC), along with the binding of Cdc20.  Once the MCC is formed and 
activated, believed to be through various phosphorylation events by the other checkpoint 
proteins, the MCC then prevents the activation of the anaphase promoting complex or 
cyclosome (APC/C) (17).  The APC complex directs the ubiquitination of several 
components including the protein securin.  This degradation of securin allows its bound 
partner, separase, to be released and cleave Scc1, a protein involved in keeping the sister 
chromatids together during the early stages of mitosis.  This frees the sister chromatids 
from each other and allows the separation and movement of the chromatids to the spindle 
poles.  Also, the APC will ubiquitinate several of the mitotic proteins marking them for 
degradation, allowing mitosis to end and the cell cycle to start anew (18, 19)  (figure 2). 
 
Role of p53 as a Checkpoint Protein: 
Overview: 
As mentioned above, cancer is a disease stemming from uncontrolled cellular 
proliferation.  In order to lose control of proliferation mutation in key cell cycle 
components or their checkpoints are necessary.  It is interesting to note that the most 
commonly mutated gene in human cancers is p53.  As previously stated, p53 serves as a 
checkpoint in both the G1/S and the G2/M phases.  This makes p53 an ideal protein for  
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Figure 2:  The mitotic spindle checkpoint.  This diagram shows the role of BubR1 as well as other 
spindle checkpoint proteins in the activation of the mitotic spindle checkpoint.  In prometaphase, 
unattached kinetochores will allow the localization of multiple checkpoint proteins including 
BubR1 and Mad2.  Once localized and activated (believe to be through phosphorylation events) 
these proteins interact with Cdc20 to inhibit the APC.  Once attachment and tension is signaled 
these checkpoint proteins become inactive and the APC is no longer inhibited and anaphase 
begins (20).  
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cancer study since insights on the mechanisms of p53 mediated cell cycle control could 
serve as the foundation for new or more effective cancer treatment strategies.  
The gene product of p53 is a protein of ~53 kDa that is made up of three domains.  
These domains include an activation domain at the amino-terminal spanning residues 1-
42, a central core containing the sequence-specific DNA-binding domain spanning  
residues 100-300, and finally a carboxyl-terminal, multi-functional domain spanning 
residues 300-399.  Each of these domains connects through a flexible linker sequence 
(21).  In the protein, there are five evolutionarily conserved regions with the first one 
being in the N-terminal activation domain and the other four found in the central 
core.  Multiple phosphorylation sites are found in both the N-terminal and C-terminal 
domains, which are used to regulate the activity of p53. (22) 
 
Activation of p53: 
After exposure to DNA damaging agents, multiple forms of DNA damage are 
induced that include double strand breaks and base alterations.  This damage leads to the 
activation of p53 through the actions of multiple kinases that phosphorylate p53 at 
multiple sites.  The kinases involved in this response include JNK, ATM and ATR (10, 
11).  In addition to the phosphorylating events at serines 15, 20, and 37, there is also a de-
phosphorylating event at serine 376 which opens a new site in p53 for interaction with 
the scaffold protein 14-3-3 (8, 23, 24).  Phosphorylation of the above serines, stabilize the 
protein and inhibit its interaction with the negative regulator protein Mdm-2.  Once 
stable, p53 is transported into the nucleus via phosphorylation of serine 392 by CK II 
where it tetramerizes and exhibits its transcriptional activity (25-27).  Unlike the rapid 
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response seen to ionizing radiation, DNA damaged induced by UV has a slower response 
time.  Since the damage caused by UV is most often the formation of bulky lesions such 
as thymidine dimers there is no immediate detection of the lesion until the replicative or 
transcriptional machinery stalls upon reaching the lesion.  Once the damage is detected; 
the stalling of RNA polymerase II causes serine 33 on p53 is phosphorylated by the CDK 
Activating Kinase (CAK) from TFIIH.  Additionally, ATR activates Chk I and Chk II 
which phosphorylate serine 20 while ATR directly phosphorylates serine 15 and 37 (28).  
As seen above in response to ionizing radiation, these phosphorylation events, lead to the 
stabilization of p53.  Once stabilized, p53 is again phosphorylated on serine 392, and 
transported into the nucleus where it tetramerizes and induces the transcription of the 
DNA damage response genes (29). The various phosphorylations of p53 lead to the 
alteration of the protein structure and expose the central core’s sequence-specific DNA-
binding domain as well as allowing the N-terminal activation domains to interact with 
other transcriptional factors such as TATA box-binding protein (TBP) and its associated 
factors (TAFs) (30) .  Finally, since p53 accumulation will sequester the cofactors 
involved in transcription, those genes that do not contain a p53 specific binding site will 
not be transcriptionally active until the level of p53 is restored to its base (31-34). 
  
Physiological role of p53: 
The activation of p53 leads to three outcomes for the cell; cell cycle arrest, 
cellular senescence, or apoptosis.  By keeping with these outcomes, p53 is able to protect 
the genome from accumulating mutations.  However, since these effects prevent cellular 
growth, p53 must be tightly regulated to prevent wasteful delay, arrest and/or 
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unnecessary apoptosis.  In many organisms, the extensive loss of cells due to up 
regulation of p53 can lead to problems which can put the entire organism at risk.  On the 
other hand, if p53 is too tightly regulated due to an over-expression of its negative 
regulators or an under-expression of the gene itself, the stability of the genome can 
become uncertain due to the lack of p53-dependent checkpoint activation.  Once 
activated, the results of the activation must be decided as to whether the cell undergoes 
cell cycle arrest or apoptosis.  This decision is based on several factors including the cell 
type, severity of damage, and the time that p53 activity was induced.   
Most of the genes induced by p53 lead to several outcomes that include cell cycle 
arrest, apoptosis, and cellular senescence.  An example of p53 induced cell cycle arrest is 
the induction of the p21 gene whose product promotes cell cycle arrest in G1/S through 
binding and inhibition of the CDKs necessary for cell cycle progression.  Activated p53 
has been shown to bind to the p21 promoter.  This binding increases transcription of the 
gene product and p21 will then form part of a quaternary complex with PCNA and the 
cyclin/CDK complex.  This quaternary complex will inhibit the cyclin/CDK activity, 
arresting the cell cycle in G1.  In addition to p21, after ionizing radiation, p53 will also 
bind to the promoter of GADD45 (growth arrest and DNA damage inducible gene) and 
activate it.  This protein will then interact with PCNA, a replication and repair factor and 
inhibit it.  With the inhibition of PCNA the cell will be unable to enter S-phase and the 
cell cycle comes to a halt.  Also, it has been shown that GADD45 is able to alter the 
chromatin accessibility which could inhibit progression into S-phase by maintaining the 
DNA in an inaccessible form to other replication factors until the damage is repaired (22, 
26).  In some cell types, activation of p21 by p53 leads to prolonged cellular arrest. 
 12
 Dependent on the damage or the cell type, the activation of p53 may induce 
apoptosis (35).  This pathway begins similar to the cell cycle arrest pathway in that p53 is 
activated, stabilized, and transported into the cell nucleus.  However, from here things 
become a bit less characterized.  While it is known that p53 mediated cell cycle arrest 
requires the protein’s transcriptional activity, initial reports seemed to indicate that the 
transcriptional activity may not be necessary and it was suggested that p53 may have both 
a transcription dependent and independent pathway to induce apoptosis. (22)  However, a 
later work showed that the induction of apoptosis through p53 is a three step process 
which requires p53 to be transcriptionally active.  From this study it was determined that 
upon the activation of p53, a subset of genes known as the p53 inducible genes (Pigs) are 
promoted.  The transcription of these genes, which code for several proteins involved in 
regulation of reactive oxygen species (ROS), will lead to an increase in the level of ROS.  
This increase of the ROS level will then work to decrease the stability of the 
mitochondrial membrane that leads to Cytochrome-C release.  Once released, 
Cytochrome-C will interact with several other apoptotic proteins ultimately leading to the 
activation of the caspase cascade that will induce genomic degradation and membrane 
blebbing, hallmarks of apoptosis. 
  
Regulation of p53 activity  
 As seen from the information presented already, the regulation of p53 is 
tightly controlled and the activating cascade requires several players to properly stabilize, 
activate and localize the protein so that it may exert its effect.  In addition to these 
activating proteins, p53 is also regulated on its transcriptional and translational levels.  
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Transcriptionally, p53 is induced in response to the stress factors such as AP-1, NF-kB 
and Myc/Max as well as the products of YY1 and NF1.  These transcription factors will 
bind to the promoter of p53 and promote transcription of the gene (36).  The p53 gene is 
transcriptionally repressed by the Pax transcription factor family (37).  Also, the viral 
protein Tax and the over expression of c-Jun have been shown to repress transcription of 
p53(38, 39).  During the translation of the p53 mRNA, p53 has been shown to be able to 
repress its own translation through the 3’ untranslated region (UTR) in human and the 5’ 
UTR in murine p53.  These UTR sequences can form stable secondary structures which 
can repress translation through interaction with the RNA binding factors.  
Though p53 is regulated both in its transcription and translation, the majority of 
its regulation is seen post-translationally.  In the cell, cytoplasmic p53 has a short lifespan 
of only a couple minutes.  The protein p53 can induce the transcription of proteins which 
attenuate its activity serving as an auto-regulatory feedback.  An example of this is the 
mdm-2 gene, whose protein product binds to p53, preventing its nuclear localization and 
promoting its degradation, is a downstream target of p53 (22, 25, 31). Thus p53 up-
regulates its own inhibitory factors, thereby assuring that p53 activity will diminish 
quickly after the DNA damage is repaired (40).  Cytoplasmic p53 is bound to the protein 
MDM-2 and ubiquitinated, targeting the protein for degradation by the 26s proteosome 
(41, 42).  In addition to this degradative pathway to regulate p53, the localization of p53 
is another way of controlling p53 activity.  For p53 to function, it must first be able to 
enter the nucleus of the cell.  To do this, p53 has a nuclear localization signal which must 
be accessible to recognition sites on the nuclear membrane and so one method of 
regulation is via the binding of other proteins which hide the signal.  One example of this 
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is the binding of p53 to Mdm-2 to prevent access of the localization domain.  Also, once 
imported into the nucleus, p53 may bind to MDM-2 and be subsequently exported.  By 
controlling the degradation or localization of p53, the cell assures that any protein present 
in the cell remains at sub-active levels until activation and stabilization of the protein is 
needed (22, 25). 
 
Effects of p53 Inactivation:  
 With p53 serving such an important role in maintaining genomic stability and 
providing the means to arrest cell cycle progression or promote apoptosis, it is no small 
wonder that mutation of p53 or the complete loss of the gene is commonly seen in cancer.  
The most commonly seen mutations of p53 are found in the DNA binding regions of the 
protein.  These mutations all serve to prevent p53 from inducing the transcription of cell 
cycle arrest or apoptotic genes (31).  Additionally, mutations of the NLS region of the 
protein have been characterized.  It has been observed that mutation of the NLS region or 
alteration of the residues lysine 305 and arginine 306 leads to the cytoplasmic 
localization of p53 and its inactivation (25).  Finally, mutation of either p53 or MDM-2 to 
prevent their dissociation will lead to a substantial reduction of inducible p53 which will 
prevent p53 mediated cell cycle arrest or apoptosis (34).  In all of these mutations, the 
inactivation of p53 leads to increased proliferation, genomic instability, and the 
accumulation of mutation due to the loss of cell cycle arrest and apoptosis.  
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Role of BubR1 as a Checkpoint Protein: 
Overview  
The protein, BubR1, is a part of the mitotic spindle checkpoint which serves to 
assure anaphase delay until the chromosomes are properly aligned on the metaphase plate 
with proper microtubule attachment and tension along all the kinotechores.  The human 
BubR1 gene is located on chromosome 15q15 and its product is considered to be one of 
the major players in the prevention of chromosomal instability (CIN).  While BubR1 
mutations are not prevalent in all cancers, studies have shown that mutations of BubR1 do 
occur in some colorectal cancers. (43)  In addition, chromosomal rearrangements of 
15q15 have been observed in some leukemias.  These rearrangements may promote the 
inactivation of BubR1 as a checkpoint control protein and increase the likelihood of 
tumor progression (44).  BubR1 is a gene found in mammals but not in yeast and has 
homology to both yeast genes BUB1 and MAD3, hence the names BubR1 (bub1-related).  
BubR1 was first identified in a study by Davenport et al. using differential expression of 
normal and leukemic mouse thymocytes.  In this study, a homologue to the yeast 
checkpoint protein Bub1 was discovered and this novel family member, named mBub1b, 
was shown to have 40% sequence similarity to murine Bub1a over 4 extended domains.  
To better understand this novel protein, Davenport et al. used the clone fragment B13 
from their differential expression studies to isolate a 3,647 base pair cDNA from the 16 
day mouse embryo cDNA library and determined some of the properties of this new 
protein (44).  As mentioned above, the BubR1 gene transcribes a message of 3,647 base 
pairs making up 23 exons with a promoter located 1,368 base pairs upstream of exon 1.   
It was also found that a GC-rich region rests 150 base pairs upstream of exon 1.  This 
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translates to a protein with 1,052 residues across four major domains.  These domains are 
a Ken-box motif, a signaling sequence for degradation,  (residues 26-28), a Mad3-like 
region (residues 52-204), a Bub3 binding domain (residues 392-433) and a kinase domain 
(residues 749-1018) (45).  The kinase domain of BubR1 is atypical in that the kinase 
domains of Bub1, BubR1 and the yeast Bub1 are more closely related to each other than 
to other kinase domains.  Even with this being the case, BubR1 contains significant 
alterations which mask its relationship to other kinases outside of the bub family.  An 
example of this is the substitutions of Bub1’s Glutamate 127 and Aspartate 170 with 
BubR1’s Asparagine and Arginine (44).  These alterations are explained in Davenport’s 
work as proofs that BubR1 has different substrates than Bub1.   Along with these 
domains, BubR1 has a destruction box sequence immediately following its amino-
terminal domain, (residues 222-230 in the mouse Bub1b) and two sequences that could 
serve as nuclear localization signals (residues 229-234 and 412-117) (44).  Also, later 
work showed that BubR1 contained a dileucine motif (residues 958-963) this motif is 
commonly seen as an adaptor beta chain recognition motif (46).  The destruction box 
sequence, RSSLAELKS, is located between the Mad3-like and the Bub3 binding 
domains and serves to promote degradation of the protein through ubiquitination of the 
lysine residues targeting the protein for destruction by the proteosome.  This destruction 
box allows the degradation of BubR1 in a cell cycle-dependent manner (44, 47).  Along 
with these various sequences and within these domains are several phosphorylation sites.  
These sites are hypothesized to serve as activators and regulators for BubR1 activity in 
the event of mitotic spindle checkpoint activations (figure 3). 
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Figure 3: The BubR1 protein.  This diagram shows the BubR1 protein and its evolutionarily 
conserved domains as well as their role in the activity of BubR1.  The Destruction box (DB) is 
located just past the N-terminal domain of the protein (containing its Mad3 like region and Ken 
box motif).  The nuclear localization sequence (NLS) is located within the kinetochore binding 
domain. 
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 Functional role of BubR1: 
As implied by its multiple structural domains and motifs, the role of BubR1 in the 
cell is complex.  The exact function and binding partners as well as the kinase substrates 
of this protein have been sought out since it was first isolated in 1998 (43, 44).  Many  
researchers have spent years on this gene and while strides have been made and some of 
its key roles determined, there is still a great deal to learn about this gene and its product.   
The isolation and study of BubR1 done by Davenport determined that the product 
was expressed in all dividing cells and highly expressed in the spleen and thymus.  This 
work showed that expression of this gene peaked around the G2/M phase of the cell cycle 
and due to its homology to Bub1, it was determined that BubR1 has a distinct role in the 
mitotic checkpoint.  This finding was confirmed in a separate study by Cahill et al. who 
examined 19 colorectal cancer cell lines that exhibited chromosomal instability (CIN) 
and found that in two of them there was a mutation of the human bub1 homologue 
BUBR1(43, 44).  One of the first studies to determine BubR1’s binding partners and 
regulation was done by Chan et al examining the interaction of BubR1 with the 
centromeric motor protein E (CENP-E).  It was found that while BubR1 levels were 
lowest in G1, it steadily increased towards mitosis.  During Mitosis, BubR1 was hyper-
phosphorylated and it was found that this hyper-phosphorylation increased the kinase 
activity of the protein (48, 49).  Their studies also showed that BubR1 was capable of 
binding to CENP-E in the cytoplasm of interphase cells through interactions of 641 
residues at its C-terminal.  Furthermore it was observed that BubR1 could localize to the 
kinetochores of unaligned chromosomes during prometaphase.  This localization would 
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occur after the localization of CENP-F but before the localization of CENP-E suggesting 
that BubR1 may phosphorylate substrates on the kinetochore to allow the binding of 
CENP-E.  Because it was accepted that BubR1 had a distinct role in the mitotic 
checkpoint and this discovery that BubR1 interacted with CENP-E, a motor protein, it 
was suggested that the BubR1/CENP-E complex served as a mechanosensor for the 
unaligned chromosome (49).  Later experiments were able to show that BubR1 was an 
essential component of the mitotic checkpoint though CENP-E was not.  Additionally, 
the kinase activity of BubR1 was examined and it was observed that while BubR1 had no 
detectable kinase activity in either interphase cells, or in mitotic checkpoint activated 
cells, through addition of the drug nocodazole, BubR1 showed a high level of kinase 
ability both for itself as well as a number of exogenous substrates using in vitro kinase 
assays.  It was determined that one role of BubR1 was to prevent normal mitotic exit until 
the chromosomes had aligned properly and this arrest was through specific interactions 
with the Anaphase Promoting Complex (APC).  In addition to this role in the mitotic 
checkpoint activation, it was confirmed that BubR1 served to monitor functions specified 
by CENP-E as a tension checkpoint (48).  In 2001, in a study by Skoufias et al. it was 
confirmed that one of the major roles of BubR1 was to sense tension across the 
chromosome’s kinetochore.  It was shown that in the event of tension loss while 
microtubule attachment was maintained, Bub1 and BubR1 returned to the kinotechore to 
delay anaphase until tension was restored.  It was suggested that BubR1 and another 
mitotic checkpoint protein Mad2 were parts of two distinct checkpoints, one sensing 
tension and the other sensing microtubule attachment (50).  However, this model was 
later proven to be incorrect through a study by Shannon et al. when it was shown that in 
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cell lines under hypothermic conditions, the major cause of prometaphase delay due to 
lack of tension, that the mitotic delay could be attenuated either through the addition of 
antibodies against Mad2 or BubR1. Additionally, it was observed that the addition of 
both antibodies did not accelerate the progression into anaphase.  This showed that 
BubR1 and Mad2 were components of the same checkpoint pathway (51).  Other 
researchers were able to provide insight into the function of BubR1 showing that once 
localized to the outer kinetochore plate, BubR1 binds to CENP-E and Bub3 (20, 52).  
This localization event is dependent on the previous localization of Bub1 and in the event 
Bub1 is missing or unable to bind to the kinetochore, the amount of BubR1 localized to 
the kinetochore is greatly reduced.  Finally, it was observed that BubR1 must first interact 
with Bub3 before it could bind to the kinetochore (53, 54).   
 
BubR1 activation and mitotic spindle checkpoint: 
In the event of tension loss or microtubule instability during mitosis, BubR1 is 
hyper-phosphorylated and becomes active.  This phosphorylation event is facilitated by 
Mad1 on the kinetochore and serves to alter BubR1 in such a way that it is able to interact 
directly with the APC as part of the mitotic checkpoint complex made up of the other 
checkpoint proteins Mad2 and Bub3 along with the APC cofactor Cdc20 or its sub-
complexes (55).  Without the presence of Mad1, while still on the kinetochore, and 
Mad2, BubR1 would not be able to interact with Cdc20 (53).  This interaction inhibits the 
activity of the APC by preventing meaningful interactions between the APC and its 
substrates (20, 45, 52, 53).  In all of these studies, it was shown that the BubR1 kinase 
domain was not necessary for the direct stoichiometric binding of BubR1 or the mitotic 
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checkpoint complex (MCC) to inhibit the APC.   In addition to direct binding of the 
MCC to inhibit the APC, Yoon et al. observed that BubR1 was able to phosphorylate 
Cdc20 in vitro and that this phosphorylation event prevented the interaction between 
Cdc20 and the APC, effectively leading to a metaphase/anaphase block (45).   
 
Additional functions of BubR1: 
Another checkpoint protein phosphorylated by BubR1 is the breast cancer 
susceptibility gene BRCA2.  The downstream effects of this phosphorylation event are 
still not clear but it is suspected that this allows interaction of BRCA2 with its substrates 
leading to cell cycle arrest (52).  In a study by Shin et al., it was suggested that the role of 
BubR1 activation may not just lie in its activities during spindle checkpoint activation but 
also that the prolonged activation of the spindle checkpoint through BubR1 could 
promote apoptosis in those cells that eventually adapted to the arrest and exited mitosis, 
effectively executing a “fail safe” mechanism to prevent the propagation of cells 
breaching the mitotic checkpoint.  This induction of apoptosis was found to be through 
the intrinsic pathway and the activation of caspase-9 leading to the subsequent activation 
of caspase-3 and apoptosis.  A study by Vogel et al. further showed that cells need a 
functional mitotic checkpoint to activate post mitotic G1 arrest (56).  Finally, Lens et al. 
found that for BubR1 to sustain its activity during prolonged checkpoint activation, the 
protein Survivin was necessary.  It was also suggested that BubR1 was a possible 
substrate for Aurora B  Kinase (47, 57).  In addition to its role in the Spindle checkpoint, 
BubR1 has been found to interact with Beta2-adaptin, a subunit of AP2, on its N-terminal 
“trunk” domain and the C-terminal kinase domain of BubR1.  AP2 is a member of the 
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assembly protein family involved in vesicular transport through the cell.  AP2 mediates 
rapid endocytosis of the plasma membrane. It was found that BubR1 is able to interact 
with B2-adaptin through out the cell cycle suggesting that BubR1 might have a novel role 
in the regulation of vesicular intracellular traffic by regulating the soluble pools of B2-
adaptin (46).   Finally, in recent work by Fang et al. it was observed that MEF cell lines 
deficient for BubR1 exhibited compromised mitotic arrest and DNA repair after DNA 
damage by UV or the drug doxorubicin.  DNA repair was found to be compromised in 
these cell lines through the down-regulation of p53, p21, phospho-H2AX and the 
enhanced degradation of PARP-1.   Taken together this strongly suggests that a 
deficiency of BubR1 leads to continued cell cycling even after exposure to DNA 
damaging agents and through the down-regulation of key components of the DNA 
damage repair pathways, allows for the increased possibility of DNA damage and 
tumorigenesis (58) 
 
Effects of BubR1 inactivation: 
 As it has been shown, BubR1 is an important component of the spindle 
checkpoint and has shown promise to play a role in several other checkpoints and cellular 
functions as well.  BubR1 became a gene of interest due to the fact that mutant forms of 
the gene were observed in two colorectal cancer cell lines and that these cell lines 
exhibited chromosomal instability.  From this it was suggested that the aneuploidy seen 
in cancer was due to the loss of chromosomal stability and that this loss was reflected 
through the mutation or loss of BubR1 (43).  The idea that mutation in BubR1 caused 
chromosomal instability and its mutation was a factor in tumorigenesis was supported by 
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the work of Oshima et al who found that in four T-cell leukemia/lymphoma cell lines, 
BubR1 was found to have two missense mutations, one nonsense mutation, and an 
internal deletion (59).  Furthermore, in breast cancer patients the aberrant expression of 
the protein encoded by the breast cancer specific gene 1 (BCSG1) has been shown to 
target BubR1 for degradation (60).   
With the ability to create knock-out mice using the gene trapping method, BubR1 
haplo-insufficient mice were able to be bred to examine the effects of the loss of one 
BubR1 allele.  By pairing mice both missing one functional allele of BubR1, it was 
determined that BubR1 was an essential gene and that embryos nullizygous for BubR1 
begin to die 6.5 days after conception and that by 8.5 days, the nullizygous embryos are 
all reabsorbed.  It was also determined that this embryonic death was due to extensive 
apoptosis (61, 62).  The heterozygous mice lived well into adulthood but still exhibited 
problems and increased susceptibility to carcinogens.  It was found that the spleens of 
heterozygous mice were enlarged with an increase in the number of mature 
megakaryocytes.  These mice exhibit anemia and defects in platelet formation.  It was 
hypothesized that this increase in spleenic megakaryocytes was due to the loss of proper 
cell division that in turn resulted in the formation of multinucleated megakaryocytes (62).  
It was also observed that mice heterozygous for the BubR1 gene trap were prone to 
tumors after exposure to azoxymethane, a known colon carcinogen.  Heterozygous mice 
exposed to carcinogens develop colon masses two months after exposure while those 
with both functional alleles did not develop masses until six to eight months after 
treatment.  It was also found that the heterozygous mice also developed tumors of the 
lung and liver, that was not observed in the wild-type mice (61).  Later, Baker et al were 
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able to produce a hypomorphic mouse that expressed only 11% of the wild-type BubR1 
level (BubR1 heterozygous mice express ~25% of wild-type levels).  These mice were 
able to survive to adulthood but showed severe phenotypes including cachexia and 
lordokyphosis from three to six months of age and had a median lifespan of only six 
months, compared to the approximate two years observed in wild-type mice.  These mice 
were also found to be infertile.  Embryonic fibroblasts of BubR1 hypomorphic mice 
showed a severely compromised spindle checkpoint and a high level of aneuploidy.  It 
was suggested in this study that BubR1 had a role in aging as those mice hypomorphic 
for BubR1 exhibited symptoms of advanced age (63).  In work done by Rao et al. it was 
observed that BubR1 insufficiency had a synergistic effect with other proliferative 
control genes in the progression of tumorigenesis.  It was observed that in a mouse strain 
exhibiting a mutation of the adenomatous polyposis coli gene (Apc), the introduction of 
BubR1 insufficiency led to a ten fold increase in the incidence of tumors in the colon.  It 
was also seen that these tumors were in advanced stages of development.  It was 
hypothesized that this increased tumor incidence was due to the role BubR1 played to 
prevent chromosomal instability. (64) 
 
Rational for Generating BubR1/p53 Compound Mutants: 
 In this study, we have analyzed the synergistic effects of p53 deletion in the 
tumorigenesis in mice deficient for BubR1.  Studies have shown that cancer is a multi-
step process that requires the inactivation of a variety of gene products involved in 
proliferation control.  Furthermore, Fearon and Vogelstein and colleagues have shown 
the necessity for p53 inactivation in human colon cancer patients (65).  Based on these 
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observations we hypothesized that the additional inactivation of the p53 tumor suppressor 
gene will either enhance the tumor susceptibility, indicated by a decrease in the lifespan, 
of the BubR1 mutant mice and/or induce the formation of colon cancer.  To measure 
tumor susceptibility we generate a compound mutant for BubR1 and p53 and monitored 
the colony for a period of two and a half years.  
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II. Materials and Methods: 
Generation of BubR1 Mutant Mice in a p53 Deficient Background: 
 In order to study the role of BubR1 in the spindle assembly checkpoint and cancer 
formation, BubR1 deficient mice were generated using embryonic stem (ES) cells 
obtained from the Mutant Mouse Resource Center at UC Davis. A gene trap approach 
was used to achieve disruption of the BubR1 gene as described earlier (66).  The gene 
trap, containing a splice acceptor and an ATG-less betagalactosidase-neomycin fusion 
cassette, was determined to have inserted into intron 2 of the BubR1 gene. The gene-
trapped ES cells, from the 129P2/ OlaHsd strain, were analyzed by PCR and Southern 
blotting to confirm the presence of the trap within the BubR1 gene. Upon confirmation, 
the mutant ES cells were used for injection into 3.5 day old blastocysts and implanted 
into a pseudo-pregnant c57 bl/6 mouse.  Nine chimeric mice were generated from these 
blastocyst injections and of these, four founder males produced germ line litters for the 
BubR1 deletion as detected by the agouti coat color. Tail clips were taken from the first 
two litters for genotype analysis. These analyses indicated equal numbers of wild type 
and heterozygous offspring consistent with the expected Mendelian ratio. Additionally, 
the heterozygous mice had no recognizable developmental defects. Heterozygous F1 
offspring from the chimera males were then crossed in an effort to obtain BubR1 
nullizygotes.  To generate compound heterozygotes, the BubR1 mutant mice were 
crossed to our p53 deficient mouse strains (67). 
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DNA Extraction: 
To obtain DNA from our mice for Southern blotting and PCR based genotyping, 
we first took tail clippings from the pups during weaning and incubated each tail 
separately in 500 µl of tail lysis buffer (50 mM Tris ph 7.5, 50 mM EDTA, 100 mM 
NaCl, 1% SDS) along with 10 µl of Proteinase K and 1.25 µl 2M DTT.  These tail 
clippings were then incubated overnight at 55-60 degrees Celsius.  After incubation, 500 
µl of phenol: chloroform (24:1) was added and the contents were mixed well.  The 
lysates were then spun in a microcentrifuge for three minutes at 13,000 rpm.  
Approximately 400 µl of the top layer (the aqueous phase) are removed into a second 
tube.  After collecting the aqueous phase, twice the volume (800 µl) of 100% ethanol is 
added to each sample.  Genomic DNA was precipitated out of solution and spooled out 
and placed into a third tube containing 50-100 µl of 5 mM Tris (10mM Tris, 1mM 
EDTA) depending on the amount of DNA recovered.  DNA was solubilized overnight 
and concentrations determined for use in southern blotting and PCR genotyping. 
 
BubR1 Genotyping: 
 To determine the BubR1 genotype, we employed a PCR based strategy.  For each 
sample, 200 ng of DNA was added to 23 µl of a PCR master mix (containing 1X PCR 
Buffer, 1.5 mM MgCl2, 0.2 mM dNTP (each), 0.2 µM of the forward and reverse 
primers, 1.0 unit of Platinum Taq DNA Polymerase).  The PCR conditions for the 
insertion and wild-type PCR were as follows:  an initial two minute denaturation step at 
94oC, followed by another denaturation step for 30 seconds at 94oC, annealing for 30 
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seconds at 54oC followed by an extension step for 135 seconds at 72oC.  The second 
denaturation, annealing, and extension steps were repeated for 32 cycles and then a final 
five minute extension step at 72oC.  For the Trap PCR the conditions were essentially the 
same with a decrease in extension time (75 seconds).  The primers used to determine if 
the trap was located in the DNA were TR2 (5’CAACACTTGTATGGCCTTGGCG-3’) 
and TR3 (5’GTGAGCGAGTAACAACCCGTC-3’).  This created a PCR product of 665 
bp and verified that the trap was located in the sample.  To determine the proper insertion 
of the gene trap, the primers GS1 (5’TTGGCAAAGCAAGAGTCAGC-3’) and TR1 
(5’CCCAACTGACCTTGGGCAAGAACATA-3’) were used, creating a PCR product of 
2.4 kb.  These two products together verified the presence and proper insertion of the 
gene trap in our BubR1 gene.  To determine if the wild-type allele was there we used the 
primers GS1 and GS2 (5’CCAGCCTAGGATACTTGGAGA-3’).  This produced a PCR 
product of 2.2 kb and indicated the presence of the undisturbed intron. 
 
Generation of Mouse Embryonic Fibroblasts (MEF): 
 Compound heterozygous crosses were performed and the pregnant female 
sacrificed at embryonic day 13.5 and the embryos removed and placed into separate 15 
ml test tubes.  Using a two ml syringe with a small bore needle, the embryo was placed 
into the syringe and pressed through the needle into cell media (DMEM,  15% FBS, 10 
units of Pen/Strep).  The cell suspension was then added to 2 large plates and incubated 
for two to three days.  Once confluent, the plates were split 1:3 and allowed to grow until 
confluent and then split again at a ratio 1:3.  A portion of the cells were isolated and used 
for experiments, while the rest of the cells were frozen in liquid nitrogen.  
 29
Cell Proliferation Assay: 
 Cell lines at the same passage were removed from liquid nitrogen storage and 
plated on 60 mm culture plates in media (DMEM, 15% FBS, 10 units of PenStrep).  At 
90% confluence, cell were trypsinized, and re-plated, onto a 100 mm plate, and allowed 
to grow to 80% confluence.  Once confluent, these plates are then trypsinized and 
counted (to count the cells, 50 ul of the collected cell suspension was added to 100 ul of 
PBS/EDTA and from that mixture 50 ul of the solution was placed onto a hemocytometer 
and the four blocks counted, divided by four and multiplied first by the dilution factor 
and then by 10,000 to get the number of cells per milliliter of cell suspension) and 
125,000 cells are seeded onto two 6-well plates and allowed to grow for one day.  On day 
two and each of the following five days, two wells from each cell line are trypsinized and 
counted.  These numbers are then plotted. 
 
Colony Forming Unit Assay (CFU): 
 Cell lines were removed from liquid nitrogen and seeded onto 60 mm plates with 
media (DMEM, 15% FBS, 10 units of PenStrep) and then passage on a three-day/four-
day cycle until passage six, seeding 400,000 cells each time.  At passage six, the plates 
were trypsinized and counted and 400,000 cells were passaged on to passage 12 where 
the second part of this study was done.  
At passages six and twelve, 2,500 cells were seeded onto each of four small plates 
and allowed to grow for nine days with media changes every three days.  After this 
growth period, the media was removed from each plate, rinsed with PBS, and 100% 
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methanol was added to each plate to fix the cells for nine minutes.  After fixing the cells, 
Giemsa stain (1.25 ml Giemsa stain, 1.5 ml 100% Methanol, QS to 50 ml) was added to 
cover the cells and allowed to incubate for 9 minutes.  After this incubation, the stain was 
removed and each plate was rinsed twice with distilled water to remove any access stain 
remaining in the plate.  After drying, colonies consisting of 40 cells or more were 
considered in the colony count.  
 
Cell Cycle Analysis: 
Low passage MEFs cell lines were seeded on to 35 mm tissue culture plates (300,000 
cells/plate) and were allowed to grow for ~24 hours before the addition of the spindle 
poison, nocodazole (125ng/ml).  Cells were trypsinized at various time points (8, 24 and 
48 hours) and collected by centrifugation.  Single cell suspensions were prepared from 
the cell pellets using a vortex, fixed in 70% ethanol, and stored at -20oC until the DNA 
content could be examined via flow cytometry for each genotype. 
 
Animal Husbandry: 
 Mice were housed in small sterilizable cages with isolation lids and fed ad lib. At 
21 days, pups were weaned and a tail clipping was taken for DNA extraction.  In this 
controlled environment, mice were examined 3 times weekly for signs of illness or tumor 
formation.  In the event a mouse was found to exhibit morbidity or have developed a 
palpable mass, it was euthanized using carbon dioxide and dissected.  During autopsy, 
tumor tissues and organs exhibiting abnormal morphology were removed and a sample of 
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it was formalin-fixed and another sample was removed and stored at -80oC to be used for 
genotyping.  
 
Southern Blotting: 
 To determine the p53 genotype of the mice, southern blot assays were performed.  
Genomic DNA (3 µg) from the tail clipping was digested with Bam HI overnight at 37oC.  
The next day the samples were subjected to electrophoresis, buffered in tris-acetate-
EDTA (40mM tris base, 20 mM acetate, 2mM EDTA) and imaged.  After imaging, the 
membrane was washed in 0.25 M HCl for 5 minutes, rinsed 4 times with distilled water 
and transferred onto a nylon membrane overnight using 0.4 N NaOH.  Following DNA 
transfer, the membrane containing the blotted DNA was rinsed with 2X SSC, dried at 
37oC and blocked with pre-hybridization buffer (1.3% SDS,  2X SSPE, 1% milk, and 2 
mg denatured salmon sperm DNA) for 5 hours at 68oC.  After blocking, the pre-
hybridization buffer was removed and 20 ml of hybridization buffer was added (10% 
dextran sulfate, 1.5X SSPE, 1% SDS, 0.5% milk) along with the radio-labeled probe. 
(1x106 cpm/ml).  After incubating overnight, the hybridization buffer was removed and 
the membrane was rinsed with 2X SSC followed by a series of solutions (Solution 1: 2X 
SSC, 0.1% SDS.  Solution 2: 0.5X SSC, 0.1% SDS.  Solution 3:  0.2X SSC, 0.2% SDS).  
Once the membrane activity is between 2,000 and 3,000 counts per minute, the 
membrane was exposed on x-ray film overnight at -80oC.  This was to reduce the amount 
of nonspecific binding of the radioprobe to the membrane, allowing for clearer results.  
The radio-labeled probe was generated using 100ng of DNA specific to exons 2-6 (a 600 
bp fragment from the Kpn I digested plasmid (LR10) containing murine p53 cDNA) of 
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the p53 gene.  This probe was then labeled with dCTP[α-32P] using random primers.  The 
specific activity of the radiolabel was 3,000 Ci/mmol.  In addition to the two possible 
bands that represent the wild type and mutant alleles, the p53 probe also binds to 
pseudogene regardless of the p53 genotype (figure 4).  
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Figure 4: Southern blot results indicate the p53 genotype.  An image of the southern blot with the 
bands labeled for 6 samples (from genomic DNA extracted from the tails of mice).  The top band 
is a pseudogene, the middle band indicating the mutant allele (in which a small portion of exon 5 
was deleted and a neomycin fusion cassette inserted) and the bottom band indicates the presence 
of the wild type allele.   
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III. Results: 
Characterization of the BubR1 gene Trap Insertion Site: 
 The 5’ RACE data obtained from the Mutant Mouse Regional Resource Center 
(MMRRC) indicated that the trap had inserted into intron 2 of the gene.  Using this data, 
we designed primers specific for exon 2 of BubR1 (GS1) and the gene trap (TR1).  PCR 
amplification produced a 2.4 Kb fragment that was specific only to the trapped allele (as 
determined by the trap-specific PCR primers TR2 and TR3).  Sequence analysis of the 
PCR product revealed that the trap had inserted into intron 2 of the BubR1 gene at base 
2,170.  Integration of the trap also resulted in the loss of the first 880 base pairs within the 
trap.  However, this did not affect the function of the trap since the splice acceptor lies 
outside these lost bases (~1,276).  Based on this information, we designed primers 
adjacent to the insertion site to amplify a 2.2 Kb fragment specific for the wild-type 
allele.  A schematic representation of the primer sites with respect to the gene trap are 
shown in figure 5.  An example of the PCR products obtained for various combinations 
of primer pairs is shown in figure 6.   
 
BubR1 Deficiency Affects Embryogenesis:  
We generated F1 heterozygotes using male chimeras and wild type females.  The 
BubR1 heterozygotes developed normally and were capable of producing progeny. In 
order to generate mice that were completely deficient for the BubR1 allele we  
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Wt allele 
 
Figure 5: The BubR1 gene and the location of the PCR primers.  This schematic representation of 
the wild-type and trapped alleles show the positions of the PCR primers used for genotyping.  In 
addition to this the blue triangle indicates the location where the gene trap inserts into the BubR1 
gene. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Trapped allele 
1 4 2 3
2.1kb
1 42 3 
3 kbGS1 GS2 
TR1 TR2 TR3 
β-gal-neo Trap (7.7kb)
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Marker Blank well 
 
Figure 6: PCR indicates the BubR1 genotype.  This gel image provides BubR1 genotype data for 
5 samples.  The marker here is a 1 kb+ ladder.  The trap PCR used the primers TR2 and TR3 
from the schematic above while the Insertion and wild type PCRs used the primer GS1 and either 
TR1 (the insertion) of GS2 (the wild type).  The trap and insertion PCR indicate the presence of 
the trapped allele (samples 1, 2 and 4). Absence of a band indicates a wild type genotype (see 
samples 3 and 5).  The wild-type PCR indicates the presence of the wild-type allele.   Absence of 
a band would signify the loss of the wild-type allele.   
      1     2       3       4      5            1        2      3      4       5       1      2       3       4      5 
12,000 
 2,000 
   650 
Size (bp) Trap PCR (665 bp) Insertion PCR (2.4 kb) Wild-Type PCR (2.2 kb) 
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intercrossed the F1 heterozygotes.  Using the PCR primers specific for exon 2 and intron 
2 in the BubR1 gene, we found that the BubR1 homozygous mutation led to embryonic 
lethality (table 1).  It was during this work that other groups published similar results and 
showed that in these nullizygous embryos, lethality was due to mitotic catastrophe and an 
up-regulation of apoptosis (62). 
 
Generation of BubR1/p53 Compound Mutants: 
Since the embryonic lethality observed in BubR1 null animals was due to 
apoptosis and a possible up-regulation of the tumor suppressor p53, a transcription factor 
for several apoptotic genes, we hypothesized that the BubR1 nullizygotes could be 
rescued in a p53 deficient background.  To test this, we generated BubR1/p53 compound 
mutants to determine if the loss of p53 would rescue this lethal phenotype.  The BubR1 
heterozygous offspring were crossed with p53 mutant mice to generate our compound 
heterozygous mice.  To determine if p53 deficiency rescued the embryonic lethality of 
BubR1 nullizygotes, various crosses were done in which both mice were heterozygous 
for BubR1 and deficient for p53 (tables 2a-c).  Overall, during the course of 39 crosses, 
243 mice were produced.  Using the PCR genotyping strategy described above, it was 
found that the progeny exhibited all the expected genotypes in their approximate ratios 
with the exception of the BubR1 nullizygotes.  This indicated that p53 deficiency does 
not rescue the embryonic lethal phenotype observed in a BubR1 nullizygous animals.  
Since p53 deficiency failed to rescue the lethality observed in the BubR1 nullizygotes, we 
wanted to learn if the deficiency was able to delay the lethal phenotype during 
embryogenesis. Since we ere unable to produce mice nullizygous for BubR1, and since  
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Table 1:  Embryonic lethality of BubR1 nullizygotes. 
 
BubR1+/- X BubR1+/-  [n=7] 
BubR1 WT BubR1 Het BubR1 Null 
11 16 0 
 
This table shows the results of multiple BubR1 heterozygous pairings.  Mice were genotyped for 
BubR1 using the PCR strategies mentioned earlier.  From these pairings no BubR1 nullizygous 
progeny were generated.  Other groups produced similar results and found that this lack of 
nullizygous progeny was due to apoptosis and reabsorption of the nullizygous embryos at 
embryonic day 6.5 (62). 
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Table 2:  p53 deficiency does not rescue the lethality of the BubR1 nullizygotes. 
a. 
 
BubR1+/- p53+/- X BubR1+/- p53+/-  [n=4] 
BubR1Het/ 
p53 Wt 
BubR1 Wt/ 
p53 Het 
BubR1 Wt/ 
p53 Null 
BubR1 Het/ 
p53 Wt 
BubR1 Het/ 
p53 Het 
BubR1 Het/ 
p53 Null 
BubR1 Null / p53 
Wt, Het, Null 
2 4 1 1 12 4 0 
b. 
BubR1+/- p53+/- X BubR1+/- p53-/-  [n=18] 
BubR1 Wt/ 
p53 Het 
BubR1 Wt/ 
p53 Null 
BubR1 Het/ 
p53 Het 
BubR1 Het/ 
p53 Null 
BubR1 Null / p53 
Het, Null 
14 12 32 17 0 
 
 
 
 
c. 
BubR1+/- p53 -/- X BubR1+/- p53-/-  [n=2] 
BubR1 Wt/ 
p53 Null 
BubR1 Het/ 
p53 Null 
BubR1 Null /  
p53 Null 
6 4 0 
 
 
 
 
A table showing the genotype of the crossed mice as well as the number of crosses [n] of each 
type and the number of offspring produced for each possible genotype.  Mice were genotyped 
using the PCR and Southern blotting strategies mentioned previously.  P53 deficiency was unable 
to rescue the lethality of the BubR1 nullizygotes even if both parents were heterozygous (a), or if 
one (b) or both parents (c) were nullizygous for p53. 
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earlier studies have shown that p53 deficiency can delay embryonic lethality of DNA 
damage response gene mutants (68, 69), we attempted to generate MEF lines nullizygous 
for BubR1.  Various crosses were set up and MEFs were generated from E10.5 and E13.5 
day embryos as explained above.  BubR1 nullizygous cell lines were not generated from 
any of the crosses, indicating that p53 deficiency was unable to delay the lethal 
phenotype at least up to E10.5 (table 3 and data not shown). 
 
BubR1 Deficiency Enhances Tumor Formation in p53 Mutant Mice: 
To determine the effect of the BubR1 and p53 gene deficiency on overall survival 
and tumor formation we monitored the mutants and wild type littermates for a period of 
two and a half years.   Mice exhibiting morbidity and signs of tumor formation were 
euthanized and autopsies were performed.  The ages of the mice were recorded on a 
spreadsheet and used to create survival curves for each genotype (figure 7).  As shown in 
the graph, the loss of one allele for either gene decreases the survivability of the mice and 
the loss of one allele in both genes further decreases the survivability implying a 
cumulative effect for the compound mutant.  The wild-type mice survived the longest 
with a median age of 104.8 weeks.  With the loss of one allele for either BubR1 or p53, 
survival decreased (63.1 weeks for the p53 heterozygous mutant and 70 weeks for the 
BubR1 heterozygous mutant).  For both of these single mutants, when compared to the 
wild type, the survival was significantly different (P value= 0.0077 for the wild type 
versus the BubR1 heterozygous mutant and P value= <0.0001 for the wild type versus the 
p53 heterozygous mutant).  When the compound heterozygous mutant was analyzed, it 
was found that the survival was decreased further (50 weeks) and that this was also 
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 Table 3: p53 deficiency is unable to delay the lethal phenotype observed in BubR1 
nullizygotes. 
 
MEF Crosses: BubR1+/- p53+/- X BubR1+/- p53+/-  [n=2] 
BubR1 Wt/ 
p53 Wt 
BubR1 Wt/ 
p53 Het 
BubR1 Wt/ 
p53 Null 
BubR1 Het/ 
p53 Wt 
BubR1 Het/ 
p53 Het 
BubR1 Het/ 
p53 Null 
BubR1 Null / p53 
Wt, Het. Null 
1 * * 2 2 6 0 
 
A table of the MEF cell lines produced from two double heterozygous mutants.  While no p53 
single mutants were produced from these two crosses, these two cell lines were available through 
previous work by the investigator. (*)  Later crosses using mice from the colony produced MEF 
lines including both the Wt/Het and Wt/Null genotypes.  At both E10.5 and E13.5 there is no 
generationof BubR1 nullizygous cell lines. 
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Figure 7: Survival of wild type, heterozygous and compound heterozygous mutant mice.  All 
mice were of mixed inbred (C57Bl/6 X 129P2/OlaHsd) background.  The percentages of tumor-
free survivors are plotted as function of age in weeks (Prism 4 statistical software, GraphPad, 
Software Inc. San Diego, CA).  Animals were monitored for tumors, morbidity or spontaneous 
death over a period of two and a half years (168 weeks).  Moribund or tumor bearing mice were 
sacrificed and necroposied.  Tumors or tissues with abnormal morphology were subjected to 
histopathological analysis to confirm their status as tumors.  
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significant when compared to the wild-type (P value= <0.0001 for the compound mutant 
versus the wild-type).  However, it was also determined the survival curves of the single 
mutation genotypes (BubR1+/+ p53+/-, and BubR1+/- p53+/+) were not significantly 
different when compared to each other (P value= 0.1418).  With this information it is 
then important to make sure that the survival curve of the double mutation is significantly 
different when compared to both of the single mutation genotypes.  It was found that for 
comparison to both of the single mutants, the survival curve of the double mutant was 
significantly different (P value= 0.005 versus the BubR1+/+ p53+/- and P value= 0.0002 for 
the BubR1+/- p53+/+).  The two p53 nullizygous survival curves were also compared and 
though not significantly different to one another (P value= 0.9755), they were significant 
when compared to the other genotypes.  However, with the complete loss of p53, the 
genotype of BubR1 has no additive effect on the survivability due to the rapid induction 
of lymphatic tumors in the p53 nullizygous background (figure 8). 
The formalin-fixed samples mentioned above were then paraffin embedded and 
made into slides for the pathologist to examine and verify the tumor presence and type.  
The majority of the tumors observed were of lymphomas of the spleen and thymus.  
While spleenic and thymic lymphomas are commonly seen in p53 deficient models, mice 
deficient for BubR1 also showed the involvement of liver and lung tumors possibly due 
to the metastasis of the primary lymphomas, something not seen in the p53 single 
mutants (figures 9 and 10) 
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Figure 8:  Survival of BubR1 mutants in p53 nullizygous background.  All mice were of mixed 
inbred (C58BL/6 X 129SP2/OlaHsd) background.  The percentages of tumor-free survivors are 
plotted as function of age in weeks.  Animals were monitored for tumors, morbidity or 
spontaneous death over a period of 2.5 years (168 weeks).  Moribund or tumor bearing mice were 
sacrificed and necroposied.  Tumors or enlarged tissues were subjected to histopathological 
analysis to confirm their status as tumors.  
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Tumor Spectrum of the Single and Compound Heterozygous Mice 
 
 
                
                                                       
 
                                                                                               
 
 
 
 
 
 
 
 
29%
29%
42%
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Figure 9:  Tumor spectrum of the single and compound 
heterozygous mutants.  The tumor spectrum is  
consistent with historical data for the p53 heterozygotes.s 
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Figure 10: Tumor Spectrum of the single and compound nullizygous mice. 
The tumor spectrum is consistent for the p53 nullizygotes.  There is no     
observed shift in the tumor spectrum possibly due to the rapid induction  
of spleenic and thymic lymphomas in the p53 nullizygous background.   
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Gene Dosage Effect of BubR1 During Tumorigenesis 
To determine if there was a loss of heterozygosity for BubR1 in the compound 
heterozygotes, we performed PCR analysis of the DNA isolated from the tumors.  Of 
the16 BubR1/p53 heterozygous mutants examined, none of the tumors had lost the wild 
type allele.  This indicates that the loss of a single copy of BubR1 gene was sufficient for 
the tumorigenic phenotype observed in the compound mutants. 
 
BubR1 Deficiency Enhances Cell Proliferation and Cell Transformation Potential: 
To better understand the effects of BubR1 deficiency on cellular proliferation we 
compared the cell growth kinetics of wild type and mutant MEFs.  Single mutant and 
compound mutant MEFs were used in cellular growth assays.  Analysis of the growth 
curves indicated that the loss of either the p53 or the BubR1 alleles resulted in an increase 
in the proliferation capacity (figure 11).  Furthermore, compound heterozygous cell lines 
had an increased proliferation rate when compared to both the wild type and the single 
heterozygous lines.  Interestingly, in the case of the p53 nullizygous mutants, BubR1 
deficiency had an additive effect on the cellular growth rate indicating that deficiency of 
BubR1 allowed a growth advantage in the p53 nullizygous cell line.     
Loss of tumor suppressor genes usually provides a growth advantage that can be 
correlated to the ability of the cells to grow in sub-optimal conditions.  To determine if 
BubR1 deficiency synergized with the ability of p53 mutant cells, MEFs, we measured 
the colony forming ability of these cells.  Colony forming assays were performed using 
the MEF cell lines generated.   Consistent with the cell growth kinetic assays, we found 
that the loss of BubR1 and p53 either alone or in  
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Figure 11: BubR1 and p53 Deficiency has a synergistic effect on cellular proliferation.  This 
representative graph shows the growth kinetics of the various BubR1/p53 genotypes and their 
growth over 5 days.  In each experiment (repeated 3 times) 125,000 cells were seeded onto each 
plate.   
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 combination increased the colony forming potential (figure 12).  Furthermore, our 
preliminary analysis of BubR1 deficiency in p53 nullizygous MEFs indicated that the  
BubR1 compound mutants (BubR1+/- p53-/-) were more susceptible to mitotic slippage 
when treated with the spindle poison, nocodazole (data not shown). 
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Figure 12: BubR1 and p53 deficiency has a synergistic effect in the transformation potential of 
MEFs.  This is a representative graph showing the CFU assay results, after nine days of growth, 
based on the genotype of each cell line.  In all the three experiments a similar trend was observed. 
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IV. Discussion 
 Tumorigenesis is a multi-step process in which the mutation or loss of one gene is 
usually insufficient to promote a cancer phenotype.  However this single loss can provide 
a growth advantage to cells and with time, start a domino effect of genetic loss in the 
organism until a mutant cell line loses cell cycle controls resulting in uncontrolled 
proliferation.  This proliferation can then feedback on itself and enhance the risk of 
genetic mutation that can ultimately lead to the formation of a tumor mass.  In a subset of 
colonic cancers, it was found that the mitotic spindle checkpoint gene BubR1 was 
mutated and it was proposed that this mutation could lead to chromosomal instability and 
an increased risk of tumorigenesis (43, 44).  Following experiments showed that mouse 
models deficient for BubR1 showed an increased susceptibility to carcinogen induced 
tumor formation, anemia, and splenomegaly (61, 62).  Additional studies have shown that 
BubR1 deficiency increased the cancer formation susceptibility in a mouse background 
known to be prone for colonic tumors (through a mutation of the Adenomatous polyposis 
coli gene) (64). 
 The purpose of our project was to examine the effects of a combined BubR1/p53 
deficiency as human cancers show a preponderance of p53 mutations along with a subset 
showing mutations in the BUBR1 gene.  Our work confirmed the results from others in 
showing that the complete loss of BubR1 was embryonic lethal (61, 62).  Additionally, 
we showed that the loss of p53 was not able to rescue or significantly delay this lethality 
during embryogenesis.  It is possible that the loss of p53 may slightly delay the lethality 
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of the BubR1 nullizygous embryos past the observed lethality from E6.5-E8.5 to E9.5, 
but this will require further work to determine the embryonic lethality at that stage. 
The tumor incidence and survival data of BubR1 mutants in the presence or 
absence of p53 provide evidence that the loss of BubR1 leads to an increased mortality as 
well as an alteration in the type of tumors observed.  In previous work examining the 
tumor incidence and lifespan of p53 deficient mouse models, it was found that the loss of 
one allele leads to an increased incidence of tumorigenesis with a specificity for 
osteosarcomas and soft tissue sarcomas by 15 months while a complete loss of the gene 
leads to the formation of lymphomas within 6 months (70, 71).  In the compound mutants 
for BubR1 and p53, the earliest incidence of tumorigenesis was observed around 36 
weeks with the mice having a median lifespan of 50 weeks.  The tumor spectrum of these 
mice was also different with the involvement of spleen, thymus, liver and lung tumors.  
The induction of lung and liver tumors are rarely observed in the p53 mutants.  We also 
compared the survival of the p53 heterozygous and the BubR1 heterozygous and found 
that there were no significant differences even though the median age of the p53 
heterozygotes were 7 weeks earlier than the BubR1 heterozygotes.  However comparison 
of the survival data between the heterozygotes and the compound heterozygotes (p53+/- 
BubR1+/-) showed a significant decrease in the median life span and an increase in the 
tumor incidence of the compound mutants.  A likely explanation of these results is that 
with the additional mutation of BubR1 there is an increased incidence of chromosomal 
instability and mitotic slippage and these two events lead to other genetic alterations and 
an increase in tumorigenesis.  This difference was not apparent in a p53 nullizygous 
background due to the fact that a complete deficiency of p53 induces a rapid 
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tumorigenesis phenotype that prevents the analysis of any additional effects of BubR1 
deficiency.   
To better understand the synergistic effects of BubR1 on p53 deficiency induced 
tumorigenesis, we studied the phenotypes of the mutants at the cellular level.  Analysis of 
cell growth kinetics showed that while the single heterozygous mutants had similar 
kinetics, the compound mutant cell lines had an increased growth rate.  This is consistent 
with the checkpoint role of both of the proteins during the cell cycle, which would confer 
a growth advantage to the compound mutant. Furthermore, the increased cellular 
proliferation rate of the compound heterozygotes translates to an enhanced tumorigenesis 
phenotype at the organismal level.  These results also verify that while p53 and BubR1 
are primarily involved in separate checkpoint systems, the loss of both the checkpoints 
leads to increased cell proliferation.  If these two proteins worked together only in a 
single checkpoint then the effects of the double mutant would not be additive but rather 
would show the same growth curve to the single mutants.  Interestingly, we observed 
significant differences in the growth rates of compound mutants that were nullizygous for 
p53 (p53-/- BubR1+/- and p53-/- BubR1+/+).  This observation provides additional evidence 
that the loss of BubR1 protein intensifies the effects of p53 loss during tumorigenesis.  
We observed a similar trend in the colony forming assays in which the loss of BubR1 
resulted in a higher transformation potential of the p53 heterozygotes and nullizygotes 
(p53-/+ BubR1+/- and p53-/- BubR1+/-). 
 In our work we were able to generate a mouse model defective for two genes 
involved in the regulation of various phases of the cell cycle.  This work has confirmed 
the results of previous studies in determining the effect of the BubR1 nullizygosity during 
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embryogenesis and extended these observations to show that p53 deficiency can not 
rescue the embryonic lethal phenotype in the BubR1 nullizygotes.  Our results indicate 
the importance of the BubR1 protein at earlier stages of mammalian development.  In this 
work, we have also shown for the first time, that the mutation of BubR1 alters the life 
span and increases the incidence of tumorigenesis and these effects are amplified in a p53 
deficient background.  The synergistic effects of BubR1 deficiency on a p53 deficient 
background are consistent with the recent finding that showed a role for the BubR1 
protein in effecting a DNA damage response after treatment with DNA damaging agents 
(58).  The initial purpose of this study was to generate a mouse model for colon cancer 
formation.  However, our data suggests that the mutant mice generated so far are not 
susceptible to colon cancers.  The lack of colon cancers is possibly due to strain specific 
differences of tumor susceptibilities seen in various inbred mouse strains (72).  Based on 
our experimental observations, we plan to back cross our BubR1 deficient mouse model 
from the C57 BL/6 strain to the Balb/C strain.  In addition, the progression of human 
colon cancer requires additional mutations that involve the activation of the RAS 
oncogene and the inactivation of the tumor suppressor genes p16 and APC.  Therefore an 
inherent disadvantage of our mouse model would be the requirement of additional 
mutations.  Nonetheless, our results suggest that the loss of the BubR1 gene can increase 
the susceptibility of tumorigenesis in mice. 
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